No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET

Schizophrenia Research
C TrichardJ L Martinot

Abstract

To investigate putative abnormalities of cortical 5-HT2A receptor density in schizophrenia, we used positron emission tomography and [18F]setoperone, a high-affinity 5-HT2A receptor radioligand, in 14 neuroleptic-free or -naive schizophrenic patients and in 15 normal controls. No significant difference between the groups was observed in the whole or regional cortical binding potential of [18F]setoperone, indicating an absence of major 5-HT2A receptor cortical density abnormalities in schizophrenics.

References

Aug 1, 1979·Archives of General Psychiatry·J P BennettS H Snyder
Jan 1, 1991·Journal of Neural Transmission. General Section·R C Arora, H Y Meltzer
Jan 1, 1988·International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology·B MaziereJ C Bisserbe
Mar 1, 1981·Archives of General Psychiatry·P M WhitakerI N Ferrier
Oct 1, 1993·Archives of General Psychiatry·M LaruelleJ E Kleinman
Jun 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J N JoyceJ E Kleinman

❮ Previous
Next ❯

Citations

Jan 2, 2003·Annals of Nuclear Medicine·W Gordon Frankle, Marc Laruelle
Sep 28, 2007·Psychopharmacology·René HurlemannAndreas Bauer
Sep 28, 2005·Anatomy and Embryology·René HurlemannAndreas Bauer
Mar 17, 2000·Brain Research. Brain Research Reviews·G K Aghajanian, G J Marek
Feb 22, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David ErritzoeBirte Y Glenthoj
Jan 19, 2011·Imaging in Medicine·Judy L ThompsonAnissa Abi-Dargham
Jun 16, 2009·Behavioural Brain Research·Susanne NikolausHans-Wilhelm Müller
Mar 18, 2004·Neuroimaging Clinics of North America·David ErritzoeAnissa Abi-Dargham
May 12, 2005·Neuropathology and Applied Neurobiology·R M CravenM M Esiri
Feb 16, 2013·Expert Opinion on Investigational Drugs·Tiago A MestreSusan H Fox
Jul 12, 2011·Expert Opinion on Investigational Drugs·Bjørn H EbdrupBirte Glenthøj
Aug 12, 2008·Schizophrenia Research·Brian DeanElizabeth Scarr
Jan 20, 2015·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Shih-Hsien LinYen Kuang Yang
Aug 15, 2013·The International Journal of Neuropsychopharmacology·Adam L Halberstadt, Mark A Geyer
Nov 18, 2005·International Review of Neurobiology·W Gordon FrankleMarc Laruelle
Aug 23, 2000·The Australian and New Zealand Journal of Psychiatry·B Dean
Jul 12, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Teresa M du BoisXu-Feng Huang
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Apr 9, 2019·The International Journal of Neuropsychopharmacology·Per StenkronaLars Farde
Mar 20, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Neva H PatelAdil Al-Nahhas
Feb 27, 2019·ACS Chemical Neuroscience·Urjita H Shah, Javier González-Maeso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here